Navigation Links
Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
Date:5/15/2012

E Mark and other international regulatory approvals.  Enrollment is expected to be completed in the first half of 2013. 

The Lotus Aortic Valve System™ is an investigational device, limited by applicable law to investigational use and not available for sale.  The device was developed by Sadra Medical, which Boston Scientific acquired in 2011.  For more information, visit www.sadramedical.com.About Aortic Valve Disease
Aortic valve disease results in dysfunction of the aortic valve, one of the four valves that control the flow of blood in and out of the heart.  Aortic valve stenosis is the process of thickening and stiffening in the valve, which can result in an abnormal narrowing of the aortic valve opening and reduction in blood flow.  Aortic stenosis is a common problem affecting approximately 3 percent of the population over age 65 and 5 percent of people older than 75.  From the onset of aortic stenosis symptoms, the average survival rate is 50 percent at two years and 20 percent at five years. 

About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com. Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be gua
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering
2. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
3. Medical Device Developers - Network at BIOMEDevice Boston Next Week
4. Boston to Host 3 Major Annual Drug Discovery Conferences, Early Bird Expiring April 27
5. Boston Scientific Launches Innovative Device Used to Prevent Stone Migration in Urologic Procedures
6. Annual Biotech and Healthcare Conferences Being Held in Boston MA, Summer 2012
7. Boston Scientific Announces Launch of PROMUS Element™ Platinum Chromium Stent System in Japan
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston on March 7, 2012
9. Boston Scientific Announces First Implants of TELIGEN® Implantable Defibrillator in China
10. Boston Scientific Receives Industrys First FDA Approval for Drug-Eluting Coronary Stent Use in Heart Attack Patients
11. Boston Scientific Launches Innovative Crossing Device to Treat Complete Blockages in Peripheral Arteries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- Growth of the U.S. nonprescription market is primarily driven ... to the OTC market. Due to an increasingly favorable ... activity over the next five years with several all ... entering the market into existing categories. If ... those with low to moderate likelihood), the market is ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, ... the second Phase III clinical study for Ozenoxacin, ... impetigo.  Medimetriks owns the exclusive U.S. rights to ... trial, conducted at 44 centers with an emphasis ... patients aged 2 months and older with a ...
(Date:7/30/2015)... Texas , July 30, 2015 /PRNewswire/ ... company focused on gynecologic disease, announced today ... financial results after the market close on ... investor conference call and webcast at 4:30pm ... 13, 2015 at 4:30pm Eastern/1:30pm Pacific  ...
Breaking Medicine Technology:Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... June 15 Jazz Pharmaceuticals, (Nasdaq: JAZZ ) ... in pain and the core symptoms associated with fibromyalgia, according ... Associated Professional Sleep Societies meeting in Seattle, WA. These ... regulatory authorities for use of sodium oxybate in the treatment ...
... MASI ), the inventor of Pulse CO-Oximetry(TM) ... that three new independent studies demonstrating the clinical accuracy ... continuous measure of patient fluid status and responsiveness were ... (ESA) Annual Congress in Milan, Italy. , ...
Cached Medicine Technology:Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia 2Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia 3Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia 4Data Suggest Sodium Oxybate Significantly Improves Pain and the Core Symptoms of Fibromyalgia 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6
(Date:7/30/2015)... ... July 30, 2015 , ... ... that the latest issue of Inclusive™ magazine, its multimedia publication focused on implant ... edition of the new issue, Volume 6, Issue 2, as well as past ...
(Date:7/30/2015)... ... July 30, 2015 , ... Boston ... the annual All-Stars Summit. Google Partners is the platform for search marketing agencies ... full support and tools necessary to run successful search marketing campaigns. Google Partners ...
(Date:7/30/2015)... ... , ... Quintessa Medical Spa is happy to offer patients the latest treatment ... for the elimination of excess tissue under the chin, referred to as submental fat. ... to offer this innovative treatment. , Developed by Kythera Biopharmaceuticals, Kybella was approved by ...
(Date:7/30/2015)... ... July 30, 2015 , ... The ... Administrator Chuck Rosenberg’s announcement of the reinstitution of National Prescription Drug Take-Back Days. ... 2015 from 10:00 AM to 2:00 PM local time. On the 26th, the ...
(Date:7/30/2015)... NC (PRWEB) , ... July 30, 2015 , ... New ... patients. Click here to read more on the Surviving Mesothelioma website. ... Rehabilitation Hospital in Missouri reviewed more than 12,000 cases of mesothelioma occurring between 1990 ...
Breaking Medicine News(10 mins):Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2
... Called Klebsiella , it could be causing gut inflammation, ... bacterium normally found in the mouth, skin and intestines might ... babies, a new study says. , Researchers found ... the intestines of all babies in their study who had ...
... PITTSBURGH, Aug. 6 General Nutrition Centers, Inc. ("GNC" ... call and webcast to report its financial results for the second ... , , To listen to this call dial ... conference identification number for all callers is 22209643. A webcast ...
... , DENVER, Aug. 6 Air ... transportation company in the world, reported financial results for the second ... 2009 flight volumes. For the quarter, revenue increased slightly from ... the six-month period, revenue increased 3% to 252.8 million, compared with ...
... , NORTH HOLLYWOOD, Calif., Aug. 6 IPC The Hospitalist Company, ... today announced financial results for the second quarter ended June 30, 2009. , ... 2008): , , , Net revenue ... , Patient encounters increased 21% to 796,000 , ...
... , , , ... , Twitter was shut down Thursday morning August 6 due to a denial ... risk solutions at Integralis, can discuss: , , - Why are ... platform that is more like a human brain than a simple website. Its users ...
... can use tools to solve problems , THURSDAY, Aug. 6 (HealthDay ... found that the members of the corvid, or crow, family can ... to bring a floating worm within reach of their beak. , ... of accuracy, using only the exact number of stones needed to ...
Cached Medicine News:Health News:Bacteria May Be Connected to Colic 2Health News:Air Methods Reports 2Q2009 Results and 3Q2009 Update 2Health News:Air Methods Reports 2Q2009 Results and 3Q2009 Update 3Health News:Air Methods Reports 2Q2009 Results and 3Q2009 Update 4Health News:Air Methods Reports 2Q2009 Results and 3Q2009 Update 5Health News:Air Methods Reports 2Q2009 Results and 3Q2009 Update 6Health News:Air Methods Reports 2Q2009 Results and 3Q2009 Update 7Health News:IPC The Hospitalist Company Reports Second Quarter 2009 Results 2Health News:IPC The Hospitalist Company Reports Second Quarter 2009 Results 3Health News:IPC The Hospitalist Company Reports Second Quarter 2009 Results 4Health News:IPC The Hospitalist Company Reports Second Quarter 2009 Results 5Health News:IPC The Hospitalist Company Reports Second Quarter 2009 Results 6Health News:IPC The Hospitalist Company Reports Second Quarter 2009 Results 7Health News:IPC The Hospitalist Company Reports Second Quarter 2009 Results 8Health News:IPC The Hospitalist Company Reports Second Quarter 2009 Results 9Health News:IPC The Hospitalist Company Reports Second Quarter 2009 Results 10Health News:IPC The Hospitalist Company Reports Second Quarter 2009 Results 11Health News:IPC The Hospitalist Company Reports Second Quarter 2009 Results 12Health News:IPC The Hospitalist Company Reports Second Quarter 2009 Results 13Health News:IPC The Hospitalist Company Reports Second Quarter 2009 Results 14Health News:Integralis Expert Resource Available to Discuss Twitter Denial of Service Attack and Web 2.0 Security 2Health News:Rooks Show Intelligence in Catching the Worm 2
Inquire...
... Optimal for Subcellular Fractionation, Proteins ... g (30,000 rpm) with fixed-angle ... 0.25 up to 85 mL ... C to 40° C • ...
... Optimal for Subcellular Fractionation, ... x g (30,000 rpm) with ... from 0.25 up to 85 ... 2° C to 40° C ...
... Optimal for Subcellular Fractionation, ... x g (30,000 rpm) with ... from 0.25 up to 85 ... 2° C to 40° C ...
Medicine Products: